Intradermal Rabies Immunization Using NanoJect: A Comparative Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

66 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-31

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is planned as a single-center, randomized, double-blind placebo-controlled, comparative Phase I, first-in-man study to assess the safety and tolerability of the NanoJect™ device, and the immunogenicity of the rabies vaccine "Vaccin rabique Pasteur®" delivered with the NanoJect™ device by ID route.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age

NCT02177032

Rabies Infection

COMPLETED PHASE3

Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects

NCT04019444

Rabies Rabies Immunisation

COMPLETED PHASE1

A Phase I Clinical Trial to Evaluate the Safety of Different Immunization Schedules of a Lyophilized Human Rabies Vaccine (Human Diploid Cell)

NCT07338786

RabiesPrevention

ENROLLING_BY_INVITATION PHASE1

A Clinical Trial of Freeze-dried Human Rabies Vaccine (MRC-5 Cells)

NCT06078423

Rabies Vaccine Adverse Reaction

COMPLETED PHASE3

Purified Rabies Vaccine for Human Use (Chick-embryo Cell)

NCT00345319

Rabies Post-exposure Prophylaxis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will enroll 66 volunteers randomly assigned to one of the three study arms. Each volunteer will receive three injections at each of three vaccination visits. Total study duration per volunteer is 2 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intradermal (ID) Vaccination Device

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vaccine injected ID with classical syringe

Right forearm, ID with NanoJect device (DebioJect™) filled with placebo (0.1mL);

Left forearm, ID with classical syringe filled with vaccine (0.1mL);

Non-dominant deltoid, Intramuscular (IM) with classical syringe filled with placebo (0.5mL).

Group Type PLACEBO_COMPARATOR

NanoJect device (DebioJect™)

Intervention Type DEVICE

The investigational device used in this study is the NanoJect™ device developed by Debiotech company.

Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus)

Intervention Type DEVICE

The comparator device used for standard ID injections is a classical syringe (1mL BD Luer-Lock™) with a 25G needle (Terumo® Neolus)

Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)

Intervention Type DEVICE

The comparator device used for standard IM injections is a classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)

Vaccin rabique Pasteur®

Intervention Type DRUG

Placebo

Intervention Type DRUG

Sodium Chloride (NaCl) 0,9%; B. Braun

Vaccine injected ID with NanoJect device (DebioJect™)

Right forearm, ID with NanoJect device (DebioJect™) filled with vaccine (0.1mL);

Left forearm, ID with classical syringe filled with placebo (0.1mL);

Non-dominant deltoid, IM with classical syringe filled with placebo (0.5mL).

Group Type ACTIVE_COMPARATOR

NanoJect device (DebioJect™)

Intervention Type DEVICE

The investigational device used in this study is the NanoJect™ device developed by Debiotech company.

Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus)

Intervention Type DEVICE

The comparator device used for standard ID injections is a classical syringe (1mL BD Luer-Lock™) with a 25G needle (Terumo® Neolus)

Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)

Intervention Type DEVICE

The comparator device used for standard IM injections is a classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)

Vaccin rabique Pasteur®

Intervention Type DRUG

Placebo

Intervention Type DRUG

Sodium Chloride (NaCl) 0,9%; B. Braun

Vaccine injected IM with classical syringe

Right forearm, ID with NanoJect device (DebioJect™) filled with placebo (0.1mL);

Left forearm, ID with classical syringe filled with placebo (0.1mL);

Non-dominant deltoid, IM with classical syringe filled with vaccine (0.5mL).

Group Type PLACEBO_COMPARATOR

NanoJect device (DebioJect™)

Intervention Type DEVICE

The investigational device used in this study is the NanoJect™ device developed by Debiotech company.

Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus)

Intervention Type DEVICE

The comparator device used for standard ID injections is a classical syringe (1mL BD Luer-Lock™) with a 25G needle (Terumo® Neolus)

Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)

Intervention Type DEVICE

The comparator device used for standard IM injections is a classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)

Vaccin rabique Pasteur®

Intervention Type DRUG

Placebo

Intervention Type DRUG

Sodium Chloride (NaCl) 0,9%; B. Braun

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NanoJect device (DebioJect™)

The investigational device used in this study is the NanoJect™ device developed by Debiotech company.

Intervention Type DEVICE

Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus)

The comparator device used for standard ID injections is a classical syringe (1mL BD Luer-Lock™) with a 25G needle (Terumo® Neolus)

Intervention Type DEVICE

Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)

The comparator device used for standard IM injections is a classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)

Intervention Type DEVICE

Vaccin rabique Pasteur®

Intervention Type DRUG

Placebo

Sodium Chloride (NaCl) 0,9%; B. Braun

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Has completed the written informed consent process.
* Is male or female aged 18 years and 50 years.
* Agrees to stay in contact with the study site for the duration of the study, provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study.
* Agrees to avoid elective surgery for the duration of the study.
* For female subjects: agrees to avoid pregnancy through the duration of the study.
* Is in good general health, confirmed by medical history, physical examination and screening laboratory tests.

Exclusion Criteria

* Oral body temperature 37.5 Celcius (C).
* History or evidence of rabies vaccination or rabies contact.
* Abnormal CBC (Complete Blood Count) laboratory values (\>10% above Upper Limit of Normal (ULN) or \>10% below Lower Limit of Normal (LLN)) and abnormal biochemistry values from blood collected at screening (\>10% above ULN or \>10% below LLN). Analysis can be repeated upon request of the clinician.
* History or evidence of autoimmune disease.
* History or evidence of any past, present, or future possible immunodeficiency state, including HIV 1 infection.
* History or evidence of chronic hepatitis, including presence of anti-hepatitis B core antibodies or anti-hepatitis C antibodies.Participation in any other investigational study during the study period.
* Received immunoglobulin or blood products within 90 days prior to study visit 2.
* Received any investigational drug therapy or investigational vaccine within 180 days prior to study.
* Received any licensed vaccine within 45 days prior to study visit 2 (note: the use of licensed vaccines medically indicated during the study is permitted at any time).
* History or evidence of any treatment that, in the opinion of the investigator, may interfere with the vaccine response or compromise the safety of the subject.
* Received Chloroquin and/or Proguanil treatment within 420 days prior to study.
* Use of immunosuppressive drugs or anticoagulants.
* All female subjects: currently pregnant or lactating/nursing; positive screening urine pregnancy test; or positive urine pregnancy test on the day of any study vaccination
* History or evidence of allergic disease or reaction that, in the opinion of the investigator, may compromise the safety of the subject (Notably: allergy to active principle, excipients, polymyxin B, Streptomycin, Neomycin).
* History or evidence of dermatologic disease that, in the opinion of the investigator, may interfere with the assessment of injection site reactions.
* History or evidence of any other acute or chronic disease that, in the opinion of the investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine or compromise the safety of the subject.
* Medical, psychiatric, occupational, or substance abuse problems that, in the opinion of the investigator, will make it unlikely that the subject will comply with the protocol.
* History or evidence of any brain disease that, in the opinion of the investigator, may interfere with the vaccine and compromise the safety of the subject.
* Abnormal urinalysis at the screening visit that, in the opinion of the investigator, is clinically significant.
* Skin coloration (skin color, tattoo, freckles) that, in the opinion of the investigator, could interfere with injection reactogenicity assessment.
* Body Mass Index (BMI)\<= 18 and =\> 33 (weight/height2). Immediate need of rabies immunization.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes